Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fecal microbiota transplantation versus vancomycin for primary Clostridium difficile infection
2018-004580-31Phase 3Terminated
- Sponsor
- Oslo University Hospital
- Start
- Jan 2019
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of vancomycin in Clostridioides difficile colitis (CDI) (2 arms), sponsored by Oslo University Hospital. Primary endpoint: Primary clinical cure without recurrence with assigned treatment alone. Started Jan 2019; status: terminated.
02
Drugs
vancomycin
03
Conditions
Clostridioides difficile colitis (CDI)
Beyond the preview
Go deeper on 2018-004580-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004580-31.